LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -306.44% | -261.49% | -186.61% | 209.26% | 221.83% |
| Total Depreciation and Amortization | 60.95% | 75.32% | 64.64% | 72.29% | 53.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 178.59% | 161.88% | 154.44% | -122.83% | -146.40% |
| Change in Net Operating Assets | -109.90% | -48.44% | 14.56% | -11.21% | 78.13% |
| Cash from Operations | -527.30% | -2,459.58% | -43.58% | -38.65% | 130.27% |
| Capital Expenditure | -93.00% | -29.84% | -21.39% | 78.98% | 47.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -118.14% | 24.03% | 24.03% | 48.72% | 46.56% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.18% | -21.20% | -12.98% | -325.62% | -334.57% |
| Cash from Investing | -54.92% | -2.97% | 1.27% | 9.46% | -10.46% |
| Total Debt Issued | 57.91% | 173.53% | 152.29% | 434.67% | 188.45% |
| Total Debt Repaid | -125.21% | -108.60% | -110.75% | -259.83% | -101.22% |
| Issuance of Common Stock | 141.25% | -62.91% | -71.86% | -72.36% | -86.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -72.39% | -54.00% | -54.21% | -304.74% | -127.44% |
| Cash from Financing | 16.38% | 74.84% | 6.29% | 4.26% | -5.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.08% | 164.54% | -18.16% | 36.83% | 2,050.03% |